RG 7795

Drug Profile

RG 7795

Alternative Names: ANA 773; RG7795

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Anadys Pharmaceuticals
  • Developer Anadys Pharmaceuticals; Roche
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Discontinued Hepatitis C; Solid tumours

Most Recent Events

  • 01 Jul 2015 Phase-II clinical trials in Hepatitis B in Switzerland (PO)
  • 02 Feb 2012 Phase-I clinical trials in Hepatitis C in Netherlands (PO)
  • 02 Feb 2012 Anadys Pharmaceuticals terminates a phase IIa trial in Hepatitis C in Netherlands (ANA773-602; EudraCT2011-000728-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top